Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene  by Edwards, Stephen M. et al.
Am. J. Hum. Genet. 72:1–12, 2003
1
Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline
Mutations in the BRCA2 Gene
Stephen M. Edwards,1,* Zsofia Kote-Jarai,1,* Julia Meitz,1 Rifat Hamoudi,2 Questa Hope,1
Peter Osin,4 Rachel Jackson,1 Christine Southgate,1 Rashmi Singh,1,3 Alison Falconer,1,3
David P. Dearnaley,1,3 Audrey Ardern-Jones,3 Annette Murkin,1,3 Anna Dowe,1,3 Jo Kelly,1
Sue Williams,1 Richard Oram,1 Margaret Stevens,1 Dawn M. Teare,5 Bruce A. J. Ponder,6
Simon A. Gayther,6,† The Cancer Research UK/British Prostate Group UK Familial Prostate
Cancer Study Collaborators,‡ British Association of Urological Surgeons Section of Oncology,‡
Doug F. Easton,5 and Rosalind A. Eeles1,3
1Translational Cancer Genetics Team and 2Molecular Genetics Team, Section of Cancer Genetics, Institute of Cancer Research, and 3Royal
Marsden National Health Service Trust Hospital, Sutton, Surrey, United Kingdom; 4Department of Histopathology, University College of
London, London; and 5Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Labs, and 6Cancer Research UK Human
Cancer Genetics Research Group, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom
Studies of families with breast cancer have indicated that male carriers of BRCA2 mutations are at increased risk
of prostate cancer, particularly at an early age. To evaluate the contribution of BRCA2 mutations to early-onset
prostate cancer, we screened the complete coding sequence of BRCA2 for germline mutations, in 263 men with
diagnoses of prostate cancer who were 55 years of age. Protein-truncating mutations were found in six men
(2.3%; 95% confidence interval 0.8%–5.0%), and all of these mutations were clustered outside the ovarian-cancer
cluster region. The relative risk of developing prostate cancer by age 56 years from a deleterious germline BRCA2
mutation was 23-fold. Four of the patients with mutations did not have a family history of breast or ovarian cancer.
Twenty-two variants of uncertain significance were also identified. These results confirm that BRCA2 is a high-
risk prostate-cancer–susceptibility gene and have potential implications for the management of early-onset prostate
cancer, in both patients and their relatives.
Introduction
Many studies have demonstrated that prostate cancer
(PRCA) exhibits significant familial aggregation, partic-
ularly at a young age (reviewed by Eeles et al. 1999).
Segregation analyses have suggested that this familial
clustering is consistent with the existence of high-pen-
etrance prostate-cancer–susceptibility alleles. Despite
this, linkage searches in families with multiple cases of
PRCA have been inconclusive. Loci on chromosomes
1q24, 1q42, 1p36, Xq27, and 17p11 have been mapped
(Smith et al. 1996; Berthon et al. 1998; Xu et al. 1998;
Gibbs et al. 1999), and the specific candidate genes
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HPC1 (Carpten et al. 2002 [RNASEL; MIM 601518
and MIM 180435]) and HPC2 (Tavtigian et al. 2001
[MIM 605367]) have been identified as high-risk PRCA
genes, but none has thus far been definitively confirmed.
One other gene that has been implicated in PRCA
predisposition is BRCA2 (MIM 600185). The associ-
ation with this gene was first suggested by studies in
Iceland: Arason et al. (1993) found an excess risk of
PRCA in families with multiple cases of breast cancer
in Iceland, the majority of which have subsequently
been shown to segregate a single BRCA2 mutation,
999del5 (Thorlacius et al. 1996). Johannesdottir et al.
(1996) found that 2.7% of patients with PRCA who
were aged !65 years carried this mutation, compared
with ∼0.5% of the general population. Sigurdsson et al.
(1997) estimated a PRCA relative risk of 4.6 in male
first-degree relatives of patients with breast cancer in
families segregating the 999del5 mutation. This asso-
ciation has been supported by a large collaborative
study from the Breast Cancer Linkage Consortium
(BCLC 1999). This study, based on 173 families har-
boring BRCA2 mutations, estimated a relative risk of
4.65 (95% CI 3.48–6.22) for PRCA in male BRCA2
gene carriers. The estimated relative risk rose to 7.33
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in patients diagnosed before the age of 65 years. In
contrast, studies based on the Ashkenazi Jewish founder
mutation 6174delT have not found a strong association
between this mutation and PRCA risk (Struewing et al.
1997; Lehrer et al. 1998; Hubert et al. 1999; Nastiuk
et al. 1999; Wilkens et al. 1999; Vazina et al. 2000).
There is consistent evidence for loss of heterozygosity
of the BRCA2 region in PRCAs, particularly those at
an advanced stage (Cooney et al. 1996; Melamed et al.
1997; Edwards et al. 1998; Watanabe et al. 1998; Hyyt-
inen et al. 1999).
In a previous study (Gayther et al. 2000), we screened
for BRCA2 mutations in 38 patients with PRCA who
had a family history of the disease. Deleterious muta-
tions were found in 2 of the 16 patients who received
diagnoses before the age of 60 years (at ages 52 and 56
years), whereas no mutations were found among the 22
older patients (who received diagnoses at or after the
age of 60 years), providing further evidence of an in-
creased risk of PRCA at young ages in BRCA2mutation
carriers. To establish the contribution of BRCA2 mu-
tations to early-onset PRCA, we have now screened a
total of 263 men diagnosed at ages 55 years, who
were unselected for family history.
Material and Methods
Patients
Patients were recruited through the Cancer Research
UK/British Prostate Group (formerly “CRC/BPG”) UK
Familial Prostate Cancer Study and the British Associ-
ation of Urological Surgeons Section of Oncology, over
the period 1992–1999. Three hundred and twelve pa-
tients who received diagnoses before the age of 56 years
were identified through records of participating clini-
cians. This represents ∼50% of patients who received
diagnoses in the United Kingdom over the corresponding
period. Patients were enrolled regardless of family his-
tory. Seven (2.2%) of the patients invited to participate
had died before being approached, 4 (1.3%) declined to
participate, and a further 37 (11.9%) did not provide a
questionnaire or blood sample, leaving 264 patients to
be analyzed.
All but one of the patients in the study had disease
that was classified as adenocarcinoma of the prostate.
The one exception was the youngest patient in the study,
diagnosed at age 24 years with a low grade sarcoma.
This patient was excluded from these analyses. The re-
maining 263 patients received diagnoses between the
ages of 32 and 55 years (mean 51 years). Eleven (4%)
of the patients from this group were of black African or
Caribbean descent, and the remainder were white. De-
tails of prostate and other cancers in first-degree relatives
of the patients were obtained by questionnaire.
DNA Isolation
Lymphocytes were collected from patients and were
stored in EDTA at 70C until required. Lymphocyte
DNA was extracted by routine methods (Edwards et al.
1997).
PCR
PCR and thermocycling was conducted as described
by Edwards et al. (2001). Forty-fiveBRCA2 primer pairs
(M. Stratton and S. Gayther, personal communication)
were used. The longer exons were amplified as subfrag-
ments and were numbered accordingly; there are four
fragments for exon 10 (10.01–10.04), 17 fragments for
exon 11 (11.01–11.17), and two fragments each for ex-
ons 14 and 27. Exons 5/6 and 23/24 were amplified in
the same fragment. Primer sequences and PCR condi-
tions are available from the authors’ Web site.
Mutation Screening
Samples were analyzed by fluorescent mutation de-
tection (F-MD) as described by Edwards et al. (2001).
PCR products were mixed robotically (as many as 12
fragments per sample), which allowed the entire BRCA2
gene of an individual to be screened in four lanes of an
ABI 377. Heteroduplexes were identified by the presence
of more than one peak (band shift) for a specific PCR
product. Where band shifts were found, the mixed and
unmixed PCR products were rerun on F-MD for con-
firmation. When PCR fragments were too weak or con-
tained nonspecific amplimers, they were not placed in a
post-PCR multiplex mix; these fragments were run on
F-MD separately.
Sequencing
After confirmation of a band shift, the sample was
reamplified by PCR from stock DNA, and sequencing
was conducted to characterize mutations through use of
an ABI Prism dRhodamine Terminator Cycle Sequencing
Ready Reaction Kit and an ABI377 Genetic Analyzer,
with both forward and reverse PCR primers.
Nomenclature
Sequence variants were categorized as either “dele-
terious,” “polymorphisms,” or “variants of uncertain
significance” (VUS). Since no amino-acid substitutions
in BRCA2 have been shown to be clearly disease as-
sociated, the category of deleterious mutations was re-
stricted to those that result in a truncated protein (frame-
shift insertion or deletion, nonsense mutation, or known
pathogenic splice-site alteration). Polymorphisms were
those with reported population frequencies 11%. All
other missense variants in the coding and noncoding
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Figure 1 F-MD traces of deleterious alterations.Heteroduplexes
are seen as band shifts from normal (N) and mutant (M) amplimers
on F-MD gels. When band shifts were detected, samples were repeated
at least once.
regions were categorized as VUS (Frank et al. 2002;
Breast Cancer Information Core [BIC] Web site).
Statistical Methods
Confidence intervals for the prevalence ofBRCA2mu-
tations among patients with PRCA were computed un-
der the assumption that (given that the prevalence was
relatively small) the number of mutations followed a
Poisson distribution and, hence, that the variance of the
was given by the reciprocal of the num-log (prevalence)
ber of observed mutations. Estimates of BRCA2 prev-
alence in the general population were derived from two
previous studies (Peto et al. 1999; Antoniou et al. 2002).
Confidence limits for the prevalence estimate in the Peto
et al. (1999) article were derived using a similar Poisson
assumption based on the observed number of mutations;
confidence limits for the estimate in the Antoniou et al.
(2002) study are given in that article. These estimates
were combined into a single inverse variance-weighted
estimate. Confidence limits for the relative risk of PRCA
in BRCA2 mutation carriers were computed by assum-
ing that the variance of the was thelog (relative risk)
sum of the variances of the in patientslog (prevalence)
with PRCA and the in the generallog (prevalence)
population.
Results
Mutation Detection (F-MD) and Sequencing
Examples of band shifts seen by F-MD are shown in
figure 1. Five frameshift mutations were identified, in
patients aged 47, 48, 52, 52, and 53 years at PRCA
diagnosis (table 1). In addition, we found one splice-site
mutation (IVS17-1grc), in a 44-year-old patient. This
mutation would be expected to result in skipping of exon
18 and has been reported six times previously as a splice-
site mutation, on the BIC Web site. We have therefore
classified this as a deleterious mutation. The sequence
electropherograms of these mutations are shown in fig-
ure 2. All of the truncating mutations were found in
white patients. Twenty-two variants of uncertain signif-
icance (VUS) in 24 patients (table 2) and 26 polymor-
phisms (table 3) were also identified.
Family History of Cancer
Of the six patients with protein-truncating mutations,
one had a family history of PRCA. Two (PRY 086 and
PRY 012) had a family history of breast/ovarian cancer
(fig. 3). The sister of PRY086 was diagnosed with ovar-
ian cancer, and four of his female relatives were diag-
nosed with breast cancer (three before age 60 years). A
paternal aunt of PRY012 received a breast cancer di-
agnosis at age 68 years. Three of the mutation carriers
had no family history of breast or ovarian cancer or
PRCA.
Discussion
We have analyzed the entire coding region of theBRCA2
gene in a total of 263 patients with PRCA who received
diagnoses at or before the age of 55 years, and we have
found six protein truncating mutations (2.3%; 95% CI
0.8%–5.0%). This is likely to be an underestimate of
the true frequency, since, like other mutation screening
methods, our method will not have been able to detect
large deletions or rearrangements, and some of the mis-
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Deleterious Alterations Found in 263 Patients with Early-Onset Prostate Cancer
PATIENT ID
EXON/
INTRON
(I)a
AGE AT
DIAGNOSIS
(years)
NUCLEOTIDE
CHANGE
PROTEIN
EFFECT BIC
FAMILY HISTORY (RELATIONSHIP, AGE [IN YEARS] AT DIAGNOSIS)
Prostate Cancerb Breast or Ovarian Cancer Other Cancer
PRY 012 11.02 48 2558insA Stop 782 Yes No Breast (aunt, 68) Larynx (father, 57; grandfather), cervix (aunt),
lung (uncle; uncle, 56), liver (grandmother,
73)
PRY 042/201c 11.15 52 6710delACAA Stop 2167 Yes Brother, 48 No Pancreas (grandmother, 55)
PRY 095 12 47 7084delAAAAG Stop 2291 No No No No
PRT 033 15 53 7772insA Stop 2536 No No No No
PRY 086d 18 52 8525delC Stop 2776 Yes No Breast (grandmother; mother, 58;
aunt, 58; cousin, 38); ovarian (sister,
46)
Lung (uncle, 59)
PRY 108 I17 44 IVS17-1grc Splicing error Yes No No No
a The longer exons were amplified as subfragments and were numbered accordingly; see the “Material and Methods” section for explanation. Intronic (I) sequences were present at
the beginning and ends of shorter coding sequences.
b In first- and second-degree relatives.
c This mutation was also found by Gayther et al. (2000).
d PRY 086 also had another missense mutation 3′ to the deletion 8365ArG (T2713A).
5Figure 2 Electropherograms of mutations. Left column, normal sequence. Right column, mutant sequence. The arrow (f) shows the
position of the mutation.
Table 2
BRCA2 VUS Found in Patients with Early-Onset Prostate Cancer
EXON/INTRON (I)a AMINO ACID CHANGE NUCLEOTIDE CHANGE PROTEIN DOMAIN (WHERE KNOWN)b
CONSERVATION
COMPARISON
WITH MOUSEc
(%)
DESCRIPTION
ON BICd
NO.
FOUND
IN THE
PRESENT
STUDY
FAMILY HISTORY (TYPE OR NO.
RECORDED, AGE [IN YEARS]
AT DIAGNOSIS)
Prostate
Cancer
Breast
Cancer
Other
Cancer
3 Y42C 353ArG Transcriptional activation 100 UV (37) 1 No No No
10.01 S326R 1206CrA P/CAF interaction, HAT activity 150 UV (7) 1 No No No
10.03 I505T 1742TrC 100 UV (21) 1 No No No
11.01 Q713L 2366ArT !50 UV (1) 1 No No No
11.03 D935H 3031GrC 100 … 1 No 1 (50) No
11.03 D935N 3031GrA 100 UV (20) 1 No No Esophagus
11.04 L1019V 3283CrG BRC repeats, Rad51 interaction 100 UV (5) 1 No No No
11.06 I1275M 4053ArG BRC repeats, Rad51 interaction 100 … 1 No No Liver, uterus
11.07 L1457F 4599GrC BRC repeats, Rad51 interaction 100 … 1 No No Liver, uterus
11.11 N1730Y 5416ArT BRC repeats 100 … 1 No No Pancreas, lung
11.11 G1771D 5540GrA 150 UV (6) 1 1 (86) 1 (44) No
11.12 S1871N 5840GrA BRC repeats 0 UV (1) 1 No No No
11.13 D2005V 6242ArT BRC repeats, Rad51 interaction 150 … 1 No No No
11.16 Y2222C 6893ArG 100 … 1 No No No
18 D2665G 8222ArG 100 UV (8) 1 No 1 (63) Leukemia (12)
18 A2717S 8377GrT 100 UV (19) 2 No No Brain (77)e
20 E2856A 8795ArC 100 UV (29) 1 No No Colon, unkown
22 K2950N 9078GrT 100 UV (15) 1 3 (46, 57, 77) No No
25 Y3098H 9520TrC !50 UV (6) 1 No No Kidney (34)
2 5′UTR ArC 214ArC … … 1 1 (70) No No
I6 IVS6-19crt intron 6-19crt … UV (5), S (6) 2 No No No
I17 IVS17-1grc intron 17-1grc Splice site S (6 Myr) 1 No No No
a The longer exons were amplified as subfragments and were numbered accordingly; see the “Material and Methods” section for explanation. Intronic (I) sequences were present at the
beginning and ends of shorter coding sequences.
b P/CAF (transcriptional coactivator protein), HAT (histone acetylase transferase), BRC (30 amino acid repeats)
c Amino acid conservation was scored by the BESTFIT program (Wisconsin Computing Group) as 100% identical, 150% (indicates amino acid pairs having matrix scores 10.5), !50%
(indicates positive scores !0.5%), or 0% (no similarity) (Connor et al. 1997).
d Values in parentheses represent the number of times there is an entry for the given mutation in the BIC database. UV p unclassified variant equivalent to VUS - variants of unknown
significance, S p splice site, Myr p Myriad Genetics.
e Two A2717S mutations were detected separately in two patients; one of these patients received a diagnosis of brain cancer at age 77 years.
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Table 3
BRCA2 Polymorphisms Found in Patients with Early-Onset Prostate Cancer
Exon/Intron (I)a
Amino Acid
Change
Nucleotide
Change
Protein Domain
(Where Known)
BIC Classification (No. Recorded);
% Global Heterozygosityb
2 5′UTRGrA 203GrA P (9); 26
10.01 N289H 1093ArC P (7), UV (1); 12
10.02 N372H 1342ArC P/CAF interaction P (7); 42
10.02 G425G 1503ArG P/CAF interaction No
10.02 S455S 1593ArG P/CAF interaction P (6); 11
11.01 G637G 2139TrC No
11.01 H743H 2457TrC P (2); 13
11.03 Q961Q 3111GrA P (1), UV (1); 0.6
11.03 N991D 3199ArG BRC repeats, Rad51 interaction P (2); 15
11.04 K1132K 3624ArG P (6); 34
11.04 P1088P 3492TrC No
11.05 V1269V 4035TrC P (3); 23
11.06 L1356L 4296GrA P (1)
11.07 D1420Y 4486GrT BRC repeats, Rad51 interaction P, UV (103); 3
11.09 Q1562Q 4914ArG BRC repeats, Rad51 interaction No
11.09 D1575D 4953CrT BRC repeats, Rad51 interaction No
11.12 T1915M 5972CrT P (1), UV (4); 5
11.13 R2034C 6328CrT BRC repeats, Rad51 interaction UV (65); 0.6c
14.01 S2414S 7470ArG P (8), UV (1); 25
19 V2820V 8688ArC No
22 A2951T 9079GrA P (33), UV (5); 0.6
27.02 K3326X 10204ArT P (2), UV (154); 1.2
27.02 R3370R 10338GrA P, UV (2)
27.02 I3412V 10462ArG P (1), UV (81); 2.4
I8 IVS856crt 90956crt P (1); 2.4
I24 IVS24-16trc I24-16trc P (1), UV (3)
a The longer exons were amplified as subfragments and were numbered accordingly; see the “Material and Methods”
section for explanation. Intronic (I) sequences were present at the beginning and ends of shorter coding sequences.
b Data on global heterozygosity were obtained from Wagner et al. (1999). UVp unclassified variant equivalent to VUS,
P p polymorphism.
c Listed as “UV” on BIC; however, we consider this to be a polymorphism. Wagner et al. (1999) also state this.
sense variants may be disease causing. The BCLC has
estimated that 78% of families that show linkage to
BRCA2 have demonstrable truncating mutations in the
gene (D. Easton, personal communication). On the basis
of this sensitivity, we estimate the overall prevalence of
BRCA2 mutations in early-onset PRCA to be 2.9%
(95% CI 1.0%–6.4%).
Patients in this series were selected solely on the basis
of age at diagnosis, without regard to family history or
disease severity. Among patients identified by partici-
pating clinicians, 180% of patients were included, and
only seven had died before they could be included. Thus,
although some selection bias cannot be ruled out, this
series should be reasonably representative of early-onset
PRCA in general.
Comparison of our prevalence estimate with the prev-
alence of BRCA2 mutations in the general population
can provide an estimate of the relative risk of early-
onset PRCA in carriers. The frequency of BRCA2 mu-
tations in the general U.K. population has not been
estimated directly but has been estimated indirectly
from the frequency of mutations in patients with early-
onset breast cancer. In separate studies, Antoniou et al.
(2002) estimated a carrier frequency of 0.14% (95%
CI 0.07%–0.28%) and Peto et al. (1999) estimated a
frequency of 0.12% (0.07%–0.20%). On the basis of
the average of these two estimates, the relative risk of
early-onset PRCA is ∼23-fold (95% CI 9–57). This is
significantly higher than the 7.3-fold estimated from the
BCLC study, for patients diagnosed before age 65 years
( ), consistent with an increasing trend in rel-Pp .025
ative risk with early age at diagnosis (although both
estimates have wide confidence limits). The estimated
cumulative risks of PRCA by age 55 and 65 years in
the general population are ∼0.06% and 1.50%, re-
spectively, on the basis of recent England and Wales
cancer registration rates (Parkin et al. 1992). We there-
fore estimate the absolute risk of PRCA in BRCA2 car-
riers to be ∼1.3% by age 55 years and 10% by age 65
years.
Thompson et al. (2001) found that the risk of PRCA
was lower in carriers of BRCA2 mutations in the ovar-
ian cancer cluster region (OCCR; nucleotides 3035–
6629) than in carriers of other mutations (relative risk
8
9Figure 3 Pedigrees of patients with PRCA who have deleterious mutations. The index patient is indicated with an arrow. Sites of cancer
and ages at diagnosis and years of birth (if available) are shown. All trees have had details of other unaffected individuals altered to preserve
anonymity. These changes do not alter the inference of the study.
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Table 4
Family History of Prostate Cancer and Other Cancers (Data Available for 263 Patients)
No. of
Patients
Frequency
(%)
Patients with PRCA family history:
In one first-degree relative 35a 13.3
In two first-degree relatives 6 2.3
In three or more first-degree relatives 7 2.6
Total 48 18.2
Patients with breast and/or ovarian cancer family history:
Ovarian cancer in one first-degree relative 11 4.2
Ovarian cancer in two first-degree relatives 2 .7
Ovarian cancer in three or more first-degree relatives 1 .4
Total 14 5.3
Breast cancer in one first-degree relative aged !60 years 15b 5.7
Breast cancer in two first-degree relatives aged !60 years 3 1.1
Breast cancer in three or more first-degree relatives aged !60 years 1 .4
Total 19 7.2
Breast cancer diagnosed at age !60 years and ovarian cancer in first-degree relatives 2b .7
Patients with prostate and breast cancer family history:
Breast cancer diagnosed at age !60 years and PRCA in first-degree relatives 6 2.3
Patients with any other cancer family history:
Any cancer in one first-degree relative 79c 30.0
Any cancer in two first-degree relatives 38 14.4
Any cancer in three or more first-degree relatives 35 13.3
Total 152 57.7
a Includes PRY 042 (6710delACAA), who has a brother with PRCA.
b Includes PRY 086 (8525delC), who has four relatives with breast cancer and one with ovarian cancer.
c Includes PRY 012 (2558insA), who has a first-degree relative with laryngeal cancer.
0.48). Mutations in this region, which is coincident with
the BRC repeat domain (Bignell et al. 1997) responsible
for RAD51 binding, are also associated with a reduced
risk of breast cancer but a higher risk of ovarian cancer.
In this regard, it is interesting to note that all six mu-
tations found in our study lie outside the OCCR.
The positional effect noted above would also be con-
sistent with the apparently weaker association found in
studies of the Ashkenazi Jewish founder mutation
6174delT, which lies within the OCCR. Another factor
may be the high prevalence of screen-detected disease
in the United States. The BCLC (1999) noted that the
relative risk was higher in families from Europe than
those from North America, suggesting that BRCA2 pre-
disposes predominantly to symptomatic rather than
screen-detected disease.
Of the six patients with deleterious BRCA2 muta-
tions, one (PRY 042) had a family history of PRCA.
The overall contribution of BRCA2 mutations to the
familial aggregation of PRCA is small, however. Forty-
eight patients in the study (18%) had a first-degree rel-
ative with PRCA (table 4), of which at most one quarter
would occur at population incidence rates (the familial
risk of PRCA in first-degree relatives is at least fourfold
at ages younger than 60 years; reviewed by Eeles et al.
[1999]). Therefore, we estimate that BRCA2mutations
account for ∼6% ( ) of the excess familial2/[75%# 48]
risk of the disease. From a clinical viewpoint, therefore,
a family history of PRCA alone would not be a strong
indication for BRCA2mutation screening. On the other
hand, only two patients in the study had first-degree
relatives with both breast cancer diagnosed before age
60 years and ovarian cancer, one of whom had an iden-
tified mutation. Therefore, in this situation, a family
history of early-onset breast cancer/ovarian cancer was,
as expected, a strong predictor ofBRCA2mutation pos-
itivity. The ascertainment by early onset of PRCA was,
however, the greatest predictor of BRCA2 mutation
positivity with respect to PRCA susceptibility.
In addition to the frameshift mutations, we found 24
VUS (22 distinct variants, 2 of which were observed
twice; see table 2). Twenty of these (19 distinct variants)
were nonsynonymous missense mutations in the coding
region, and 4 were sequence variants in the 5′-UTR and
intronic regions. Of the 19 nonsynonymous VUS, 6 have
not been reported to the BIC database. The overall fre-
quency of VUS (9%) is similar to the frequency of 13%
found by Myriad Genetics’ sequencing of 10,000 in-
dividuals (Frank et al. 2002) and suggests that the ma-
jority of these variants are not disease associated. It is
possible that a subset of the variants is deleterious, but,
unfortunately, the significance of an individual missense
variant is very difficult to assess. Variants may be eval-
uated on the basis of segregation with disease in fam-
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ilies, population frequency, conservation across species,
and predicted functional significance, but these are
rarely definitive. We note that 13 of the 22 VUS are
100% conserved between human and mouse (overall
amino acid identity between the human and mouse
BRCA2 is ∼60%; see table 2). Three of these (I1275M,
L1457F, and N1730Y) are within the BRC repeat do-
main. Two of the VUS found are 100% conserved be-
tween human, mouse, and pufferfish (exon 18 D2665G
and A2717S). As an illustration of the difficulties in
classifying these variants, the Y42C variant detected in
our study severely compromises the transcriptional ac-
tivating function of the BRCA2 protein, on the basis of
a yeast functional assay (Milner et al. 1997), suggesting
that it may be disease associated. However, the variant
has been observed to occur concurrently with other del-
eterious mutations and not to segregate with disease in
families with breast cancer (Myriad Genetics, personal
communication), demonstrating that the variant cannot
be a high-risk mutation. It is, of course, possible that
some of these variants or polymorphisms confer a more
moderate risk of PRCA, as has been demonstrated for
the N372H polymorphism and breast cancer (Healey
et al. 2000).
The inconclusive nature of genetic linkage studies in
PRCA suggests that the genetics of the disease are highly
complex, and therefore, if mutations in other candidate
PRCA susceptibility genes exist at frequencies similar
to BRCA2, high-throughput mutation screening may be
required to identify them. This study has demonstrated
that BRCA2 mutations, which are individually rare in
the population, are responsible for a significant fraction
of early-onset PRCA cases outside of families with mul-
tiple cases of breast-ovarian cancer, and therefore,
BRCA2 is currently the only high-risk gene for which
definitive evidence of susceptibility to PRCA, from mul-
tiple studies, is available.
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